← Back to Clinical Trials
Recruiting NCT07579455

NCT07579455 Acute Pharmacokinetics of Create Wellness Gummies in Healthy Adults

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07579455
Status Recruiting
Phase
Sponsor University of Oklahoma
Condition Creatine Absorption in Healthy Adults
Study Type INTERVENTIONAL
Enrollment 16 participants
Start Date 2026-06
Primary Completion 2026-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 45 Years
Study Type INTERVENTIONAL
Interventions
Create Wellness Creatine GummiesCreatine Monohydrate Powder

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 16 participants in total. It began in 2026-06 with a primary completion date of 2026-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to compare blood creatine levels following acute oral supplementation of Create Wellness creatine gummies to creatine monohydrate powder.

Eligibility Criteria

Inclusion Criteria: * Adults between the ages of 18-45 yrs * Body mass index of \<35 kg/m2 * Recreationally active \[(≥30 minutes of moderate-intensity physical activity per week as defined by the International Physical Activity Questionnaire (IPAQ)\] * Healthy and free from major diseases as determined from screening call and health history questionnaire. * Agrees to complete pre-assessment guidelines (8-hour fast from caloric foods and beverages, 24-hour abstention from vigorous physical activity, caffeine, alcohol, and tobacco). Exclusion Criteria: * Chronic kidney disease, liver disease, chronic obstructive pulmonary disease, or cancer. * Currently using medications that may directly impact the primary outcomes including: diuretics and corticosteroids). * Currently using creatine monohydrate * Severely impaired hearing or speech or inability to speak English.

Contact & Investigator

Central Contact

Sam R. Moore, PhD

✉ samray@ou.edu

📞 4053252542

Principal Investigator

Sam R Moore, PhD

PRINCIPAL INVESTIGATOR

University of Oklahoma

Frequently Asked Questions

Who can join the NCT07579455 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 45 Years, studying Creatine Absorption in Healthy Adults. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07579455 currently recruiting?

Yes, NCT07579455 is actively recruiting participants. Contact the research team at samray@ou.edu for enrollment information.

Where is the NCT07579455 trial being conducted?

This trial is being conducted at Norman, United States.

Who is sponsoring the NCT07579455 clinical trial?

NCT07579455 is sponsored by University of Oklahoma. The principal investigator is Sam R Moore, PhD at University of Oklahoma. The trial plans to enroll 16 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology